International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-2 doi: 10.5281/zenodo.15161713
Original Research Article
Calculating the level of Uric acid in order to determine the impact of diseases with clinically diagnosed Sepsis
Published
April 4, 2025
Abstract

Background and Aim: The definition of acute organ dysfunction and infection, as well as the data sources used, influence the rates of sepsis and septic shock. This investigation was therefore carried out to highlight the relationship between morbidity and mortality and hyperuricemia in patients with clinically confirmed sepsis. Materials and Methods: The study included 150 patients in total. Blood samples were obtained from the patients in order to estimate their uric acid levels. The department of the biochemistry and medicine in RKDF Medical College Hospital & Research Center, Jatkhedi, Bhopal, Madhya Pradesh collaborated on the biochemical estimation of the uric acid level. Results: Of the 150 participants in the study, 64 patients (42.7%) had increased uric acid levels, whereas 86 patients (57.3%) had normal uric acid levels. It can be deduced that patients with type 2 diabetes mellitus were among the study population. 40% is the most prevalent comorbidity. Type 1 and type 2 diabetes, decompensated liver disease, and cerebrovascular accidents were the most common comorbidities among individuals with hyperuricemia. About 36% of research participants who had no comorbidities also experienced sepsis. Conclusion: This study shows that in patients with clinically confirmed sepsis in the intensive care unit, serum uric acid may be utilized as a predictor of death and morbidity as well as a measure of the severity of the illness. This report suggests more research on a wide foundation for verifying the observations.

Recommended Articles
Loading Image...
Volume-6, Issue-2
Citations
1761 Views
362 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved